Format

Send to

Choose Destination
Indian J Cancer. 2018 Oct-Dec;55(4):344-347. doi: 10.4103/ijc.IJC_428_18.

Clinico-pathological characteristics and treatment outcome in invasive lobular carcinoma of the breast: An Indian experience.

Author information

1
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
2
Department of Medical Oncology, Fortis Memorial Research Institute, Gurgaon, Haryana, India.
3
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
4
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
5
Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, Haryana, India.
6
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.

Abstract

BACKGROUND:

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and accounts for 10%-15% of all breast cancers in the west. There is a scarcity of data on ILC from the Indian subcontinent. This report intends to present the patterns of care, survival outcomes, and prognostic factors of ILC treated in a tertiary care institute.

MATERIALS AND METHODS:

This retrospective analysis included consecutive patients diagnosed with ILC and registered at our Institute between 2009 and 2016.

RESULTS:

We included 97 patients with a median age of 53 years (range 28-80). American Joint Committee on Cancer (7th edition) stage distribution was stage I-8.24%, stage II-45.36%, stage III- 34.10%, and stage IV-12.30%. Bilateral breast cancer was seen in 8 cases. Estrogen receptor, progesterone receptor, and HER 2/neu positivity was 90%, 85%, and 9%, respectively. Triple-negative breast cancer constituted 5% of cases. Twenty-nine events were recorded (systemic and locoregional relapse) with a median follow-up of 3.5 years. Three years relapse-free survival (RFS) and overall survival were 80% and 60%, respectively. Bones were the most common site of metastasis. Age <45 years [HR-1.4 (0.8-2.1), P < 0.001] and advanced clinical tumor stage [T4, HR-2.1 (1.1-3.8), P = 0.001] were associated with poor RFS.

CONCLUSION:

ILC constituted 2.5% of breast cancer cases at our institute. Triple negativity and HER-2/neu positivity were seen in 9% and 5% of cases, respectively. Age <45 years and advanced clinical tumor stage were associated with poor RFS.

KEYWORDS:

Invasive lobular carcinoma; outcome; pathological characteristics

PMID:
30829268
DOI:
10.4103/ijc.IJC_428_18
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center